Effectiveness of Systane PRO for Mild to Moderate Dry Eye Disease

Completed · Phase 4

Conditions studied: Dry Eye Disease (DED)

In brief

The primary objective of this study is to show that consistent use of Systane PRO over a 30 period will significantly improve the signs and symptoms of Dry Eye Disease and decrease patients' ocular surface disease index score for patients diagnosed with mild-moderate (DED).

Key facts

Study ID

NCT07639034

Run by

Gordon Schanzlin New Vision

People needed

33

Starts

2025-11-01

Expected to finish

2026-02-01

Last updated by the study team

2026-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 and older with mild-moderate DED (as determined by an OSDI score between 13-22).

You may not qualify if…

• Patients unwilling to discontinue all concomitant ophthalmic medications and dry eye therapies for the duration of the study.

Where it is running

• Gordon Schanzlin New Vision Institute — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.